Could Biologically Enhancing Our Morality Save Our Species?

Could Biologically Enhancing Our Morality Save Our Species?

A human head pictured with a red heart in the place of a brain.

(© blacksalmon/Fotolia)


Keep ReadingKeep Reading
Julian Savulescu
Professor Julian Savulescu has held the Uehiro Chair in Practical Ethics at the University of Oxford since 2002. He has degrees in medicine, neuroscience and bioethics. He directs the Oxford Uehiro Centre for Practical Ethics within the Faculty of Philosophy, and co-directs the interdisciplinary Wellcome Centre for Ethics and Humanities in collaboration with Public Health, Psychiatry and History. In 2017, he joined the Murdoch Children’s Research Institute, spending four months per year as Visiting Professorial Fellow in Biomedical Ethics where he is working to establish a program in biomedical ethics, and Melbourne University as Distinguished International Visiting Professor in Law. He is Editor of the Journal of Medical Ethics and received an honorary doctorate from the University of Bucharest in 2014. (Photo credit: Murray Bransgrove)
How sharing, hearing, and remembering positive stories can help shape our brains for the better

Across cultures and through millennia, human beings have always told stories. Whether it’s a group of boy scouts around a campfire sharing ghost stories or the paleolithic Cro-Magnons etching pictures of bison on cave walls, researchers believe that storytelling has been universal to human beings since the development of language.

But storytelling was more than just a way for our ancestors to pass the time. Researchers believe that storytelling served an important evolutionary purpose, helping humans learn empathy, share important information (such as where predators were or what berries were safe to eat), as well as strengthen social bonds. Quite literally, storytelling has made it possible for the human race to survive.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

A new type of cancer therapy is shrinking deadly brain tumors with just one treatment

MRI scans after a new kind of immunotherapy for brain cancer show remarkable progress in one patient just days after the first treatment.

Mass General Hospital

Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.

But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.